PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Recs

1
Player Avatar pavlos1971 (99.68) Submitted: 1/2/2013 3:58:59 PM : Underperform Start Price: $5.54 PDLI Score: -10.44

Short in RL@7.31

Featured Broker Partners


Advertisement